Antifungal prophylaxis in the intensive care unit: Who should get it?

Critical Care Medicine

Volumn 34, Issue 4, 2006, Pages 1286-1287

  Rex, John H ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antifungal therapy; Candida; Intensive care unit; Meta analysis; Prophylaxis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE;

CANDIDA; CANDIDIASIS; EDITORIAL; HIGH RISK PATIENT; HUMAN; INFECTION SENSITIVITY; INTENSIVE CARE UNIT; MORTALITY; MYCOSIS; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR;

ANTIFUNGAL AGENTS; HUMANS; INTENSIVE CARE; INTENSIVE CARE UNITS; MYCOSES; RISK FACTORS;

EID: 33645798646     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000208110.36504.19     Document Type: Editorial

References (15)

1. Gudlaugsson O, Gillespie S, Lee K, et al: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-1177
2. Rex JH, Sobel JD: Prophylactic antifungal therapy in the intensive care unit. Clin Infect Dis 2001; 32:1191-1200
3. Lipsett PA: Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: Concepts and considerations. Clin Infect Dis 2004; 39:S193-S199
4. Ostrosky-Zeichner L: Prophylaxis and treatment of invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2004; 23:739-744
5. Pelz RK, Hendrix CW, Swoboda SM, et al: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548
6. Eggimann P, Francioli P, Bille J, et al: Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072
7. Vardakas KZ, Samonis G, Michalopoulos A, et al: Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34:1216-1224
8. Garbino J, Lew DP, Romand JA, et al: Prevention of severe Candida infections in non-neutropenic, high- risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717
9. Sharpe MD, Ghent C, Grant D, et al: Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: A prospective, randomized, double-blind study. Transplantation 2003; 76:977-983
10. Winston DJ, Pakrasi A, Busuttil RW: Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729-737
11. Slotman GJ, Burchard KW: Ketoconazole prevents Candida sepsis in critically ill surgical patients. Arch Surg 1987; 122:147-151
12. Trick WE, Fridkin SK, Edwards JR, et al: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627-630
13. Mora-Duarte J, Betts R, Rotstein R, et al: Caspofungin Invasive Candidiasis Study Group. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029
14. Hernandez S, Lopez-Ribot JL, Najvar LK, et al: Caspofungin resistance in Candida albicans: Correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 2004; 48: 1382-1383
15. Goodman D, Pamer E, Jakubowski A, et al: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002; 35: E35-E36